Bard PowerPort lawsuits allege that implanted catheter devices used during chemotherapy and other long-term treatments can fracture, migrate, cause serious infections, and contribute to dangerous blood clots.
The Bard PowerPort is placed beneath the skin and connected to a catheter that enters a major blood vessel. Plaintiffs claim that flaws in certain catheter materials can cause the device to deteriorate after implantation, exposing patients to vascular damage, emergency surgery, sepsis, thrombosis, pulmonary embolism, and other serious injuries.
The federal lawsuits are consolidated in MDL No. 3081 in the District of Arizona. Bellwether trials began in April 2026. The first trial produced a partial defense result but left the central design-defect claim unresolved. The next trial, involving a fractured catheter, is scheduled to begin on August 18, 2026.


